Onco-cardiology Guideline-Trends in Japan

Advances in treatment have led to improve survival of patients with cancer, however, cancer therapy-related cardiovascular toxicity(CTR-CVT)from cancer treatment remain a leading cause of treatment-associated morbidity and mortality across cancer survivors. Onco-cardiology has become a cardiology subspecialty oriented to the prevention, diagnosis, treatment and follow up of CTR-CVT in cancer patients throughout all stages of cancer therapy and in the survivorship period. The field is rapidly growing and the Japanese Onco-Cardiology Society(JOCS)was founded in October 2017. Although only a few guidelines in the field of Onco-cardiology have been published, the Japanese Society of Medical Oncology and JOCS organized practical guidelines committee for management of Onco-cardiology in 2019 in recognition of the increasing need for guidelines. The committee began the making of recommendations according to Minds Handbook for Clinical Practice Guidelines Development. The guideline-creation committee proposed 16 clinical questions in consideration of PICO format, which described the population, intervention, control, and outcomes. A literature search was performed using the PubMed (MEDLINE), additionally we did a hand searched. After systematic review analysis, we should shift 11 questions to either background questions or future research questions because of little evidence. The guideline of Onco-cardiology was published on March 2023. In this review, I describe outlines of 5 clinical questions.

Published by Gan to kagaku ryoho. Cancer & chemotherapy, 2023. The guideline itself is at the source linked here.

pubmed.ncbi.nlm.nih.gov/37800284/